
Katharina T Prochazka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5842097/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia. Haematologica, 2019, 104, 516-523.	3.5	65
2	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. International Journal of Molecular Sciences, 2021, 22, 13311.	4.1	54
3	NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes. Cancer Research, 2017, 77, 2375-2386.	0.9	24
4	Immunohistochemistry for câ \in myc and bclâ \in 2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematological Oncology, 2020, 38, 277-283.	1.7	19
5	The CXCR4–CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro. International Journal of Molecular Sciences, 2019, 20, 4740.	4.1	14
6	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. Supportive Care in Cancer, 2021, 29, 5197-5207.	2.2	6
7	Immunohistochemical double hit score enhances <scp>NCCN</scp> – <scp>IPI</scp> and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma. British Journal of Haematology, 2018, 183, 142-146.	2.5	4
8	Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival. Scientific Reports, 2018, 8, 14528.	3.3	4
9	Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome. Blood Cancer Journal, 2018, 8, 79.	6.2	4
10	The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma. Pathology and Oncology Research, 2020, 26, 2831-2833.	1.9	2
11	Chronic lymphocytic leukaemia—what is new and notable in 2021, with aÂspecial focus on COVID-19. Memo - Magazine of European Medical Oncology, 2021, 14, 224-227.	0.5	1
12	Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL. Blood, 2019, 134, 1519-1519.	1.4	1
13	Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas. World Journal of Gastrointestinal Oncology, 2022, 14, 153-162.	2.0	1
14	Bcl2 inhibitor venetoclax +/â^' Anti-CD20: what do deep remissions mean?. Memo - Magazine of European Medical Oncology, 2022, 15, 45-48.	0.5	1
15	Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients: A Real-world Perspective. HemaSphere, 2021, 5, e621.	2.7	0
16	Impact of TP53 Mutated Subclones in Acute Myeloid Leukemia. Blood, 2018, 132, 1483-1483.	1.4	0